Metastatic prostate cancer is generally not curable with current treatments. Once prostate cancer has spread to distant parts of the body, the goal of treatment shifts from eliminating the disease to controlling it for as long as possible. The five-year relative survival rate for distant-stage prostate cancer is about 40%, based on cases diagnosed between 2016 and 2022. That said, “not curable” does not mean “not treatable,” and many men live years or even a decade or more with metastatic disease depending on how their cancer responds to therapy.
Why Metastatic Prostate Cancer Is Considered Incurable
When prostate cancer metastasizes, it typically spreads to bones, lymph nodes, or organs like the liver and lungs. At that point, cancer cells have entered the bloodstream or lymphatic system. Even if treatment eliminates every detectable tumor, microscopic deposits can remain and eventually regrow. This is why oncologists describe the disease as manageable rather than curable. Treatments can slow growth, shrink tumors, relieve symptoms, and extend life significantly, but they rarely eliminate the cancer entirely.
The Exception: Oligometastatic Disease
A small subset of men fall into a category called oligometastatic disease, meaning the cancer has spread to only a few spots. These patients sometimes receive treatment with curative intent. In a prospective trial published in European Urology, men with rising PSA levels after surgery and radiation underwent advanced imaging scans. About 53% were found to have a limited number of detectable recurrences that could be targeted with highly focused radiation (called stereotactic ablative radiotherapy) or surgery.
This approach aims to eliminate every known site of disease. While long-term data are still maturing, some of these patients achieve undetectable PSA levels after treatment, essentially showing no measurable evidence of cancer. This is not the same as a guaranteed cure, since hidden cells may still exist, but it represents the closest thing to curative treatment available for metastatic prostate cancer today. Not every patient qualifies. You typically need very few metastatic sites, a relatively low PSA, and no prior hormone therapy.
How Treatment Works for Most Patients
For the majority of men with metastatic prostate cancer, treatment follows a sequence that can span years. The backbone of therapy is hormone treatment, which cuts off testosterone that fuels cancer growth. This works because prostate cancer cells depend heavily on male hormones to survive and multiply.
When the cancer still responds to hormone suppression, it’s classified as hormone-sensitive. At this stage, doctors now combine hormone suppression with newer drugs that block additional hormone signaling pathways, or sometimes with chemotherapy. Real-world data from 2020 to 2023 show that about 53% of men in the U.S. received hormone suppression alone for hormone-sensitive disease, while the rest received combination therapy, which guidelines now favor.
Eventually, the cancer finds ways to grow despite very low testosterone levels. This is called castration-resistant disease, and it requires a shift in approach. The most common first treatments at this stage are drugs that further target hormone pathways (used in about 62% of patients) or chemotherapy (about 22%). Many patients cycle through several lines of treatment over the course of their disease.
Genetic Testing Can Change Your Options
One of the most meaningful developments in metastatic prostate cancer treatment is genetic testing. Certain inherited or tumor-specific mutations, particularly in genes involved in DNA repair like BRCA2, open the door to targeted therapies that wouldn’t otherwise be available.
Men whose tumors carry these DNA repair mutations can be treated with a class of drugs called PARP inhibitors, which exploit the cancer cell’s inability to fix its own DNA. In the PROfound trial, men with these mutations who received a PARP inhibitor went roughly twice as long before their cancer progressed compared to men on standard therapy (7.4 months versus 3.6 months). Interestingly, men with BRCA2 mutations also respond unusually well to platinum-based chemotherapy. In one study, 75% of men with BRCA2 mutations saw their PSA drop by at least half on a platinum regimen, compared to just 17% of men without the mutation.
Genetic testing also helps predict how well standard treatments will work. Men with DNA repair gene mutations tend to become resistant to hormone therapy faster, progressing in about 12 months compared to 19 months for men without those mutations. Knowing this upfront can help guide treatment sequencing. If you have metastatic prostate cancer and haven’t had genetic testing, it’s worth discussing with your care team.
Immunotherapy and Radioligand Therapy
Prostate cancer has historically been resistant to most immunotherapy approaches, but one option exists for men with castration-resistant disease and minimal symptoms. A treatment called sipuleucel-T, which trains the patient’s own immune cells to attack prostate cancer, was the first therapeutic cancer vaccine approved by the FDA for any cancer type. In its landmark trial, it extended median survival by about four months (25.8 months versus 21.7 months). The three-year survival rate was notably better: 34% versus 11%.
Radioligand therapy represents a newer approach. It delivers a radioactive molecule directly to cancer cells by targeting a protein on their surface. While initial comparisons of one such therapy against standard chemotherapy did not show a clear overall survival difference between the two, the treatment offers another option for men who have already been through multiple lines of therapy.
Managing Bone Health
Prostate cancer commonly spreads to bone, and both the cancer itself and long-term hormone therapy weaken the skeleton. Bone complications, including fractures and spinal cord compression, are a major concern. Two types of bone-protecting medications are used: bisphosphonates and a drug that blocks a protein involved in bone breakdown.
A systematic review of 12 trials involving over 5,200 men found that these treatments meaningfully reduce bone-related complications. The most effective options reduced skeletal events by roughly 16% to 28% compared to no treatment. Beyond medications, hormone therapy carries its own bone risks, contributing to osteoporosis, muscle loss, weight gain, hot flashes, fatigue, mood changes, and increased risk of heart disease and diabetes. Weight-bearing exercise and monitoring bone density become important parts of long-term care.
What “Living With” Metastatic Prostate Cancer Looks Like
Because treatment can extend life for years, many men with metastatic prostate cancer live in a pattern of treatment, monitoring, adjustment, and more treatment. PSA blood tests are used regularly to track how well therapy is working. A dropping PSA generally signals that treatment is effective, while a rising PSA often prompts a change in approach.
The side effects of treatment become a central part of daily life. Hormone therapy alone can cause fatigue, erectile dysfunction, cognitive changes, insomnia, and loss of muscle mass. Adding other therapies brings additional side effects. Managing these while maintaining quality of life is an ongoing conversation between patients and their care teams.
The 40% five-year survival rate for distant-stage disease is a population average that masks enormous variation. Some men, particularly those with limited spread, low tumor volume, and cancers that respond well to initial treatment, live well beyond five years. Others with aggressive disease or poor treatment response face a shorter timeline. The trajectory depends heavily on the biology of the individual cancer and how many effective treatment options remain available as the disease evolves.